Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 519-527

  Lance Cowey, C ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Angiogenesis inhibitor; AV 951; Metastatic renal cell carcinoma; RCC; Targeted therapy; Tivozanib; VEGF inhibitor

Indexed keywords

AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CD68 ANTIGEN; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; PAZOPANIB; PLACEBO; PLACENTAL GROWTH FACTOR; RECOMBINANT INTERFERON; SCATTER FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANOREXIA; ASTHENIA; CLEAR CELL CARCINOMA; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DRUG DEVELOPMENT; KIDNEY NEOPLASMS;

CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DISCOVERY; HUMANS; KIDNEY NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84879346616     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S31442     Document Type: Review

References (32)

1. Siegel R, DeSantis C, Virgo K, etal. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
2. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991-5004.
3. Wiesener MS, Münchenhagen PM, Berger I, etal. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 2001;61(13):5215-5222.
4. Gnarra JR, Tory K, Weng Y, etal. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85-90.
5. Shuin T, Kondo K, Torigoe S, etal. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994;54(11): 2852-2855.
6. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:4-10.
7. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163(2):408-417.
8. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):148-154.
9. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. Aug 1999;17(8):2530-2540.
10. Rini BI, Halabi S, Rosenberg JE, etal. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422-5428.
11. Rini BI, Halabi S, Rosenberg JE, etal. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-2143.
12. Escudier B, Pluzanska A, Koralewski P, etal; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111.
13. Escudier B, Bellmunt J, Négrier S, etal. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28(13):2144-2150.
14. Motzer RJ, Hutson TE, Tomczak P, etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2): 115-124.
15. Motzer RJ, Hutson TE, Tomczak P, etal. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22): 3584-3590.
16. Sternberg CN, Davis ID, Mardiak J, etal. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
17. Rini BI, Escudier B, Tomczak P, etal. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
18. Escudier B, Eisen T, Stadler WM, etal. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
19. Escudier B, Eisen T, Stadler WM, etal. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318.
20. Hudes G, Carducci M, Tomczak P, etal; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
21. Motzer RJ, Escudier B, Oudard S, etal; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456.
22. Motzer RJ, Escudier B, Oudard S, etal; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
23. Eskens FA, de Jonge MJ, Bhargava P, etal. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011;17(22):7156-7163.
24. Nosov DA, Esteves B, Lipatov ON, etal. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol. 2012; 30(14):1678-1685.
25. Motzer RJ, Nosov D, Eisen T, etal. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol. 2012;30 Suppl:Abstr 4501.
26. Eisen T, Sternberg CN, et al. Detailed comparison of the safety of tivozanib hydrochloride versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial. European Society of Medical Oncology 2012 Congress. Abstract 795PD.
27. Kabbinavar FF, Srinivas S, Hauke RJ, etal. Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J Clin Oncol. 2011;29 Suppl: Abstr 4549.
28. Hutson TE, Rathmell K, Hudes GR, etal. A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol. 2012;30 Suppl:Abstr TPS4686.
29. Robinson MO, Lin J, Feng B, etal. Correlation of a tivozanib response biomarker identified in a preclinical model with clinical activity in a phase II study in renal cell carcinoma (RCC). J Clin Oncol. 2010;28 Suppl:Abstr e13564.
30. Pfizer. A study in patients with non-small cell lung cancer testing if erlotinib plus SU011248 (sunitinib) is better than erlotinib alone (SUN1058). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00265317. NLM identifier: NCT00265317. Accessed August 1, 2011.
31. Escudier BJ, Porta C, Bono P, etal. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol. 2012;30 Suppl:Abstr CRA4502.
32. AVEO Oncology. AVEO Reports Second Quarter 2012 Financial Results [press release]. Cambridge, MA: AVEO Oncology; 2012. Available from: http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=1721417&highlight=. Accessed November 15, 2012.